In a research note that was distributed to customers and investors on Thursday, the equity research analysts at StockNews.com lowered their recommendation for Smith & Nephew (NYSE: SNN), moving it from a “buy” rating to a “hold” one. In addition, they moved it from a “buy” rating to a “hold” one.
Several other equity research specialists have disclosed their findings about the company. Morgan Stanley published a research note on Smith & Nephew on October 18, announcing that it would begin covering the company. They ranked the company as having “equal weight,” according to their system. Citigroup started including Smith & Nephew as a topic of discussion in their research reports on Monday, December 12. They suggested that an interested party purchase the company. On November 28, 2017, UBS Group shifted its recommendation on Smith & Nephew from “neutral” to “sell,” signaling a bearish sentiment toward the company. The price target that Barclays had established for Smith & Nephew was decreased from GBX 1,550 ($18.83) to GBX 1,530 ($18.59) in a research note that was published on Tuesday, October 4. There is one analyst who recommends selling shares of the company, five analysts who say investors should hold onto their shares, two analysts who say investors should hold onto their shares, and two analysts who say investors should buy shares of the company. According to Bloomberg, the current consensus rating for the company is “Hold,” and the current consensus price objective is $1,362.67.
SNN shares began trading for the first time on Thursday, and the price per share opened at $26.69. The quick ratio is 0.84, the current ratio is 1.78, and the debt-to-equity ratio is 0.42. All of these numbers are relative to the total amount of debt. All these figures should be interpreted in light of the overall sum owed. The moving averages for the previous 50 days at the company are $25.21, and the moving averages for the previous 200 days are $25.79. In addition to having a market capitalization of $11.62 billion and a beta value of 0.61, the company has a price-to-earnings-to-growth ratio of 3.16. Smith & Nephew has seen a price as low as $21.77 over the past 52 weeks and a price as high as $36.68.
Recently, several institutional investors have modified the processes by which they invest their money in the company in various ways. As part of the investment portfolio overseen by SeaCrest Wealth Management LLC, approximately $59,000 was put into Smith & Nephew during the year’s second quarter. Through the third quarter, Quadrant Capital Group LLC achieved a 243.5% increase in the proportion of Smith & Nephew stock that it owned. After purchasing an additional 2,148 shares during the most recent quarter, Quadrant Capital Group LLC now owns 3,030 shares of the medical equipment provider’s stock, which is $70,000. These shares were acquired during the most recent quarter. During the third quarter, Ellevest Inc. increased its stake in Smith & Nephew by a factor of 406.4 percentage points, making the total value of its holdings more than double what it was. After purchasing an additional 2,930 shares in the company during the most recent quarter, Ellevest Inc. now has a total of 3,651 shares of stock, which gives the company a market valuation of $85,000. Benjamin F. Edwards & Company, Inc. increased their stake in Smith & Nephew by 14.6% during the third quarter by purchasing a greater percentage of Smith & Nephew stock than in the previous quarter. Benjamin F. Edwards & Company Inc. now has 3,721 shares of the medical equipment provider’s stock after purchasing an additional 474 shares during the preceding quarter. Based on the current stock price, this gives the company a value of $86,000. As a result of the purchase of these shares, the total number of shares owned by the company is now 3,721. During the first three months of this year, Zions Bancorporation, National Association increased the amount of Smith & Nephew stock owned by 44.6%. This was done to compete with other financial institutions. Zions Bancorporation N.A. now holds a total of 3,337 shares of the medical equipment provider’s stock, which has a value of $106,000 after acquiring an additional 1,029 shares during the most recent period. To the tune of 8.56% of the total number of shares issued by the company, hedge funds and other types of institutional investors hold positions.
On a global scale, Smith & Nephew plc and its affiliates are in charge of developing, producing, distributing, and marketing medical equipment. The company offers knee implant products for use in knee replacement surgeries, hip implant products for hip joint reconstruction, and trauma and extremities products, including internal and external devices for stabilizing severe fractures and correcting deformities. These products are used in knee replacement surgeries, hip joint reconstruction, and other surgical procedures. On the website of the company, you can find these various products.